Librairie scientifique
Dernières publications
Toutes les publications
Inhibiteur de protéase du VIH PPL-100/MK-8122
Articles
- Dandache, S. et al. In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2007 Nov;51(11):4036-43. Epub 2007 Jul 16.
- Stranix, B., et al. Lysine sulfonamides as Novel HIV-Protease Inhibitors: Nε-disubstituted ureas. Bioorganic and Medicinal Chemistry Letters 2004, Vol. 14, pp 3971 - 3974.
- Stranix, B., et al. Lysine sulfonamides as Novel HIV-Protease Inhibitors: Optimization of the Nε-Acyl-Phenyl Spacer. Bioorganic and Medicinal Chemistry Letters 2003, Vol. 13, pp 4289 - 4292.
Présentations
- Wu, J.J. et al. PL-100, a Next Generation Protease Inhibitor against Drug-Resistant HIV: In Vitro and In Vivo Metabolism. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) tenu à San Francisco, Septembre 2006.
- Dandache, S. et al. PL-100, a Novel Protease Inhibitor with a High Genetic Barrier. XVI International AIDS Conference, Toronto, Canada, Août 2006.
- Wu, J.J. et al. The HIV-1 Protease Inhibitor PL-100 Has a High Genetic Barrier and Selects a Novel Patterns of Mutations. XV International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications, Sitges, Espagne, Juin 2006.
- Wu, J. et al. PPL-100 and its derivatives, a novel class of potent human immunodeficiency virus type 1 protease inhibitors: resistance and pharmacokinetics. XIV International HIV Drug Resistance Workshop, Québec, Canada, Juin 2005.
- Wu, J. et al. Pharmacological and cross-resistance profiling of PL-100 and its pro-drug, PPL-100. 6th International Workshop on Clinical Pharmacology of HIV Therapy, Québec, Canada, Avril 2005.
- Sévigny, G, et al. Cross-resistance profile of the novel lysine-containing HIV-1 protease inhibitor PL-100. XIII International HIV Drug Resistance Workshop, Iles Canaries, Espagne, Juin 2004.
- Sévigny, G, et al. Improving the resistance profile of HIV-1 protease inhibitors. Protease Targets and Drug Discovery Symposium, Philadelphie, PA, É.-U., Décembre 2003.
- Stranix, B., et al. Synthesis and SAR studies of novel HIV protease inhibitors, containing a lysine backbone. 39th International Union of Pure and Applied Chemistry Congress and 86th Conference of the Canadian Society For Chemistry, Ottawa, Canada, Août 2003.
- Sévigny, G. et al. Antiviral activity of P-1946, a novel anti-HIV protease inhibitor. XII International HIV Drug Resistance Workshop, Los Cabos, Mexique, Juin 2003.
Inhibiteurs d'intégrase du VIH
Présentations
Peptide thérapeutique PCK3145
Articles
- Lamy, S., et al. A prostate secretory protein94-derived synthetic peptide PCK3145 inhibits VEGF signaling in endothelial cells: implication in tumor angiogenesis. Int. J. Cancer 2006, Vol. 118, pp 2350-2358.
- Annabi, B., et al. Inhibition of MMP-9 secretion by the anti-metastatic PSP94 derived peptide PCK3145 requires cell surface laminin receptor signaling. Anti-Cancer Drugs 2006, Vol. 17, pp 429-438.
- Annabi, B., et al. A PSP94-derived peptide PCK3145 inhibits MMP-9 secretion and triggers CD44 cell surface shedding: Implications in tumor metastasis. Clinical & Experimental Metastasis 2005, Vol. 22, pp 429-439.
- Hawkins, R.E., et al. Safety and tolerability of PCK3145, a synthetic peptide derived from prostate secretory protein 94 (PSP94) in metastatic hormone-refractory prostate cancer. Clinical Prostate Cancer 2005, Vol. 4, pp 91-99.
- Shukeir, N., et al. A synthetic 15-mer peptide (PCK3145) derived from prostate secretory protein can reduce tumor growth, experimental skeletal metastases, and malignancy-associated hypercalcemia. Cancer Research 2004, Vol. 64, pp 5370-5377.
- Shukeir, N., et al. Prostate secretory protein PSP94 decreases tumor growth and hypercalcemia of malignancy in a syngenic in vivo model of prostate cancer. Cancer Research 2003, Vol. 63 pp 2072-2078.
- Garde, S., et al. Prostate secretory protein (PSP94) suppresses the growth of androgen-independent prostate cell line (PC3) and xenografts by inducing apoptosis. The Prostate 1999, Vol. 38, pp 118-125.
Présentations
- Guérin, M., et al. Synthetic 15-mer peptide (PCK3145) derived from prostate secretory protein with in vitro and in vivo activity against non-Hodgkins lymphoma and other hematologic malignancies. ASH 49th Annual Meeting - Atlanta, Georgia, USA, December 8-11, 2007.
- Slovin, S., et al. PCK3145 - A Novel Multitargeted Signaling Agent for the Treatment of Castrate Metastatic Prostate Cancer (CMPC) AACR-NCI-EORTC International Conference - San Francisco, California, U.S.A., October 22-26, 2007.
- Slovin, S., et al. Phase I trial results of PCK3145 in patients (pts) with castrate metastatic prostate cancer (PC) – the US experience. ASCO Prostate Cancer - San Francisco, Californie, É.-U., Février 2006.
- Dulude, H., et al. PCK3145 administered weekly reduces the plasma MMP-9 level in metastatic Hormone Refractory Prostate Cancer (HRPC) patients. ASCO Prostate Cancer - San Francisco, Californie, É.-U., Février 2006.
- Panchal, C. PCK3145, a novel signal transduction inhibitor for treating late stage prostate cancer. 3rd Angiogenesis Foundation’s Annual Symposium - Boston, Massachusetts, É.-U., Octobre 2005
- Wu, J., et al. Inhibition of multiple signaling pathways by PCK3145 and its implication in the treatment of prostate cancer. Prostate Cancer Foundation - Scotsdale, Arizona, É.-U., Septembre 2005.
- Daigneault, L., et al. A synthetic peptide, PCK3145, for the treatment of hormone refractory prostate cancer. ASCO - Orlando, Floride, É.-U., Mai 2005.
- Lamy, S., et al. A prostate secretory protein 94 (PSP94)-derived synthetic peptide (PCK3145) antagonizes VEGF signaling in endothelial cells: Implications in tumor angiogenesis. AACR - Anaheim, Californie, É.U., Avril 2005.
- Garde, S., et al. Inhibition of angiogenesis and MMP-9 production by a synthetic peptide (PCK3145) in a syngeneic model of rat prostate cancer results in decreased tumor growth and skeletal metastasis in-vitro and in-vivo. AACR - Anaheim, Californie, É.-U., Avril 2005.
- Daigneault, L., et al. A synthetic peptide, PCK3145, for the treatment of hormone refractory prostate cancer. ASCO Prostate Cancer - Orlando, Floride, É.-U., Février 2005.
- Lemoyne, C., et al. Determination of PCK3145 (peptide) in human plasma by LC/MS/MS. AAPS - Baltimore, Maryland, É.-U., Novembre 2004.
- Panchal, C., et al. Development of a novel peptide drug PCK3145 derived from the naturally occurring prostate secretory protein PSP94. INCP - Zermatt, Suisse, Novembre 2004.
- Panchal, C., et al. Clinical development of a synthetic peptide, PCK3145, for treatment of Hormone Refractory Prostate Cancer patients. Prostate Cancer Foundation - Lac Tahoe, Nevada, É.-U., Octobre 2004.
- Daigneault, L., et al. Evaluation of biological activity of PCK3145 in metastatic hormone resistant prostate cancer (HRPC) using serum markers. ASCO – Nouvelle-Orléans, Louisiane, É.-U., Juin 2004.
- Hawkins, R., et al. A multiple ascending dose, open-label, phase IIa study evaluating the safety and tolerability of PCK3145 administered intravenously in patients with metastatic hormone refractory prostate cancer (HRPC). ASCO – Nouvelle-Orléans, Louisiane, É.-U., Juin 2004.
- Dulude, H., et al. Safety, tolerability, pharmacokinetic and escalating single doses of PCK3145 in patients with metastatic hormone resistant prostatic cancer (HRPC). AACR - Orlando, Floride, É.-U., Mars 2004.
- Panchal, C., et al. Development of a synthetic peptide, PCK3145, for human clinical trials involving HRPC patients. Cap Cure, New York, New York, É.-U., Novembre 2003.
- Shukeir, N., et al. A synthetic 15 mer peptide derived from prostate secretory protein (PSP94) can reduce tumor growth, skeletal metastases and malignancy associated hypercalcemia. AACR - Washington, District of Columbia, É.-U., Juin 2003.
Technologie de libération NGR
Articles
- Pastorino, F. et al. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res. 2003;63(21):7400-7409
- Curnis, F., et al. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res. 2002 62(3):867-874
Présentations
- Garde, S., et al. TVT-Dox: in vivo efficacy and in vitro molecular mechanism of action. AACR 2007, Los Angeles, California, USA, April 14-18, 2007.
- Wu, J.J., et al. A novel dual-targeting drug for the solid tumors and their vasculature. 2006 Miami Nature Biotechnology Winter Symposium Angiogenesis in Cancer and Vascular Disease, Miami Beach, Floride, Février 2006.
- Meyer, O.,et al. Assay methods for binding NGR-targeted liposomal doxorubicin using cells expressing the angiogenic marker CD13. Lipids, Liposomes & Biomembranes, new technologies, UBC, Vancouver, Canada, Juillet 2005.
- Meyer, O., et al. Preclinical efficacy of tumor vasculature targeted liposomal doxorubicin. Royal Society of Canada (RSC)/ Korean Academy of Science and Technology (KAST) 3rd Bilateral Symposium: Drug Delivery Systems, Vancouver, Canada, July 2005.
Trousse de tests PSP94
Articles
- Reeves, J., et al. Prognostic value of prostate secretory protein of 94 amino acids and its binding protein after radical prostatectomy. Imaging, Diagnosis, Prognosis, Clinical Cancer Research Res 2006;12(20) October 15, 2006
- Nam, R., et al. A novel serum marker, total prostate secretory protein of 94 amino acids, improves prostate cancer detection and helps identify high grade cancers at diagnosis. The Journal of Urology Vol. 175, 1291-1297, April 2006
- Reeves, J., et al. Identification, purification and characterization of a noval human blood protein with bnding affinity for prostate secretory protein of 94 amino acids. Biochem. J.(2005) 385, 105-114
